- Home
- ATCX vs EVAX Comparison
ATCX vs EVAX Comparison
Compare ATCX & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ATCX | EVAX |
|---|---|---|
| Founded | 2016 | 2008 |
| Country | Brazil | Denmark |
| Employees | 13 | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.0M | 23.6M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | ATCX | EVAX |
|---|---|---|
| Price | $2.60 | $3.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $13.75 | $11.67 |
| AVG Volume (30 Days) | 10.0K | ★ 11.4K |
| Earning Date | 03-16-2023 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $827,667.00 | N/A |
| Revenue Next Year | $166.45 | $328.20 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.57 | $2.52 |
| 52 Week High | $14.01 | $12.15 |
Technical Indicators
Market Signals| Indicator | ATCX | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 42.88 | 51.36 |
| Support Level | $2.79 | $3.00 |
| Resistance Level | $3.17 | $3.61 |
| Average True Range (ATR) | 0.18 | 0.13 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 53.33 | 83.08 |
Price Performance
Historical ComparisonAbout ATCX Atlas Critical Minerals Corporation Common Stock
Atlas Critical Minerals Corp is a mineral exploration and development company focused on critical minerals projects and properties in Brazil. The company's portfolio principally includes mineral properties for rare earths, graphite, titanium, copper, uranium, and nickel. It also owns mineral rights for iron ore, quartzite, gold, and diamond properties. The company's project portfolio includes the Alto Paranaiba, Malacacheta, Arcos, Goias, Tocantins, Rio Piracicaba, and other projects.
About EVAX Evaxion Biotech
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.